Review anchor
Prostaglandin E2 receptor EP2 subtype
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Prostaglandin E2 receptor EP2 subtype
CHEMBL1881
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Prostaglandin E2 receptor EP2 subtype as ChEMBL target CHEMBL1881, mapped to UniProt P43116. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL1881
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P43116
Prostaglandin E2 receptor EP2 subtype
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Prostaglandin E2 receptor EP2 subtype matters
Prostaglandin E2 receptor EP2 subtype is reviewed as Prostaglandin E2 receptor EP2 subtype (UniProt P43116); Prostaglandin E2 receptor EP2 subtype shows approved-linked disease relevance led by cardiovascular disease. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 8 approved drugs, 1236 compounds, and 215 assays, with lead potency reaching pChEMBL 10.2.
Protein context
Prostaglandin E2 receptor EP2 subtype
Prostaglandin E2 receptor EP2 subtype Sequence length is 358 aa.
Review this target as Prostaglandin E2 receptor EP2 subtype, mapped to UniProt P43116. Sequence length is 358 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P43116
Protein
Disease context
cardiovascular disease
Prostaglandin E2 receptor EP2 subtype shows approved-linked disease relevance led by cardiovascular disease. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ALPROSTADIL.
Start review with cardiovascular disease because it currently carries approved-linked support. Linked drugs include ALPROSTADIL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 8 approved drugs, 1236 compounds, and 215 assays for this target. The dominant activity type is KI. CHEMBL4217198 is the current potency anchor at pChEMBL 10.2.
Use CHEMBL4217198 as the tractability anchor when discussing potency (pChEMBL 10.2).
Activity source · ChEMBL 36 via Core Engine
8 approved
pChEMBL 10.2
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Prostaglandin E2 receptor EP2 subtype matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P43116, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why cardiovascular disease is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
1236
Total Compounds
215
Total Assays
8
Approved Drugs
IC50: 267.0, KI: 537.0, EC50: 529.0, KD: 7.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL4217198
|
10.2 | EC50 | — |
|
|
No preferred name
CHEMBL4204996
|
10.1 | EC50 | — |
|
|
No preferred name
CHEMBL3794302
|
10.0 | EC50 | — |
|
|
No preferred name
CHEMBL4205480
|
10.0 | EC50 | — |
|
|
No preferred name
CHEMBL3793515
|
9.8 | EC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
OMIDENEPAG ISOPROPYL
CHEMBL4297666
|
2022 |
|
|
TREPROSTINIL
CHEMBL1237119
|
2002 |
|
|
DINOPROSTONE
CHEMBL548
|
1977 |
|
|
LAROPIPRANT
CHEMBL426559
|
— |
Source Header